Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook

* Daiichi Sankyo press release [https://www.daiichisankyo.com/files/investors/library/quarterly_result/2025/Q2/FY2025Q2_Financial_Results_E.pdf] (OTCPK:DSKYF [https://seekingalpha.com/symbol/DSKYF]): 1H GAAP EPS of ¥70.52.
* Revenue of ¥975.35B (+10.5% Y/Y). [https://static.seekingalpha.com/uploads/2025/10/31/saupload_Screenshot_2025-10-31_142318.png]

MORE ON DAIICHI SANKYO COMPANY 

* Daiichi Sankyo Company, Limited 2026 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4836138-daiichi-sankyo-company-limited-2026-q2-results-earnings-call-presentation]
* Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript [https://seekingalpha.com/article/4831464-daiichi-sankyo-company-limited-dsnky-discusses-esmo-2025-highlights-with-focus-on-key-breast]
* Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions - Slideshow [https://seekingalpha.com/article/4831465-daiichi-sankyo-company-limited-dsnky-discusses-esmo-2025-highlights-with-focus-on-key-breast]
* Astra, Daiichi post late-stage data to show Enhertu’s potential in early breast cancer [https://seekingalpha.com/news/4505441-astra-daiichi-post-late-stage-data-enhertu]
* AstraZeneca, Daiichi win FDA review for Enhertu label expansion [https://seekingalpha.com/news/4500544-astrazeneca-daiichi-win-fda-review-enhertu-label-expansion]